3 Intraoperative Radiotherapy: Alive and Well in the Bronx

News
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 60-61

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Background/Significance

Partial breast irradiation (PBI) is an attractive option for women with early-stage breast cancer, with equivalent local control rates to whole breast irradiation (WBI). Intraoperative radiotherapy (IORT) is one method of PBI that allows women to complete adjuvant radiotherapy at the time of breast conserving surgery (BCS). In this current study, we seek to evaluate outcomes of women treated with IORT at our institution in the Bronx, New York.

Materials and Methods

This is a single-center, prospective, observational, institutional review-board–approved registry trial of patients treated with IORT using the Intrabeamsystem from January 2018 to January 2024. Eligible patients included women aged 45 years and older who were candidates for BCS with estrogen receptor–positive, cT1 to 2N0 invasive ductal carcinoma, or grade 1 to 2 ductal carcinoma in-situ (DCIS). Exclusion criteria included known BRCA mutation, neoadjuvant chemotherapy, or multicentric disease. Following BCS, patients received a single dose of 20 Gy to the lumpectomy cavity surface with 50kVp x-rays. Those with high-risk features on final pathology—positive margins with disease on re-excision, positive lymph nodes, tumor size > 3.5 cm or high-grade DCIS— were recommended adjuvant WBI. The primary outcome was locoregional recurrence. Secondary outcomes were overall survival and wound-healing complications.

Results

Between January 2018 and January 2024, 257 women were treated with IORT. The median age was 65.8 years, and most patients (76.7%) identified as non-White. Ten patients were treated with bilateral breast IORT, equating to 267 treated lumpectomy cavities. The majority of the 267 treated tumors were pathologically T1 (n = 197, 73.8%), followed by Tis (n = 37, 13.9%), T2 (n = 31, 11.6%), and T0 (n = 1, 0.4%). Forty-three patients (16.6%) were recommended adjuvant WBI due to high-risk pathology, 37 (86.0%) of whom proceeded.

Median follow-up was 3.2 years (range, 0.4-78 months), during which 6 patients had biopsy-proven ipsilateral breast tumor recurrences, yielding a recurrence rate of 2.2%. Overall survival was 98%, and 10 patients (3.9%) had wound-healing complications.

Conclusion

In our cohort of primarily minority patients, IORT demonstrated a 97.8% locoregional control rate and spared 83.4% of women from the added physical and financial toxicity of WBI. IORT may serve as an economical and safe alternative for women seeking more personalized breast cancer treatment and with limited resources for longer radiotherapy regimens.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content